Feasibility and Acceptability of Measuring Cervical Cancer Specific Patient-Reported Outcomes in Clinical Practice
Concurrent chemo-radiotherapy followed by intracavitary brachytherapy is standard of care
for patients with locally advanced cervical cancer. Although curative, this treatment is
challenging and leaves a significant proportion of women with severe toxicity, negatively
impacting their quality of life. Although most recover over time, a proportion of women do
not. Therefore, evaluation of quality of life becomes increasingly more important as cancer
specific outcomes improve. One such method is through patient-reported outcomes (PROs),
defined as "any report coming directly from the patient about a health condition and its
treatment." This prospective multi-institutional study, involving the Princess Margaret
(PM), Odette Regional Cancer Centre(ORCC) and Royal Victoria Regional Health Centre (RVH),
will assess to feasibility and acceptability of integrating a cervical cancer specific PRO
measurement tool into clinical practice. Cervical cancer patients coming for follow-up
appointments will be asked to complete the EORTC QLQ-CX24, a validated cervical cancer
specific PRO questionnaire. At the end of the study period, Feedback Forms will be completed
by participating patients and health care providers to obtain their perspectives regarding
the feasibility and acceptability of incorporating the instrument into clinical practice.
Future directions include designing an electronic platform and expanding its use in cervical
cancer clinics provincially and nationally. The data collected should help identify
disease-related symptoms, treatment-related toxicities, facilitate patient-physician
communication, shared treatment planning and target intervention strategies.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society